Clinical trial NCT01963052: ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Official title: A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Metastatic Urothelial Cancer
Keywords: Metastatic Urothelial Cancer
AGS15E
AGS15E-13-1
ASG-15ME
Pharmacokinetics of AGS15E
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Seagen Inc.
First posted: 2013-10-16
Enrollment: 93
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objectives of this study are to assess the safety, pharmacokinetics, immunogenicity and anti-tumor activity of AGS15E in subjects with metastatic urothelial cancer who failed at least one prior chemotherapy regimen for metastatic disease.

Detailed description: All subjects will receive a single intravenous infusion of AGS15E once weekly for 3 weeks of every 4 weeks. A cycle is 4 weeks. Subjects will continue treatment until disease progression, intolerability of AGS15E, investigator decision, or consent withdrawal.

In subjects who discontinue therapy without documented disease progression and who still consent to study procedures, every effort should be made to continue monitoring their disease status by radiographic imaging until progression is documented, or new anticancer therapy, or death. All subjects will continue to be followed for survival until withdrawal of consent or study closure.

If assessed as complete response (CR) or partial response (PR) per local review a confirmatory scan will be performed no less than 4 weeks from previous scan and preferably at week 5. Tumor imaging should also be performed whenever disease progression is suspected.

Images will be sent to a central third party imaging vendor for an independent assessment per RECIST version 1.1. Although the imaging studies will be reviewed by a central third party imaging vendor in a retrospective fashion, all clinical decisions will be based on the interpretation of the investigator at the site treating the subject.

Post-Treatment Follow-up Progression Free Survival:

Subjects who discontinued study treatment for reasons other than radiographic disease progression will continue for a maximum of up to 12 months following the last dose of study drug until radiologically confirmed progression, initiation of a new anticancer therapy, death, loss to follow-up or withdraw consent for further follow-up, whichever of these events occurs first. The purpose of the post-treatment follow-up is to ascertain the duration of progression-free survival for all subjects enrolled in the study.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed Transitional Cell Carcinoma of the Urothelium (TCCU) (i.e., cancer of the bladder, renal pelvis, ureter, or urethra). Subjects with Urothelial Carcinoma with squamous differentiation or mixed cell types are eligible.
* Part A: Subject must have failed at least one prior chemotherapy regimen for metastatic disease and/or is unfit for cisplatin-based chemotherapy.
* Part B: Subject must not have received any prior lines of chemotherapy in the metastatic setting (prior treatment with immunotherapy is allowed).
* Part C (CPI-Treated Expansion): Subject must have received prior treatment with a CPI in the metastatic setting
* Subjects must have measureable disease according to RECIST (version 1.1).
* Part A and C: Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Part B: Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
* Life expectancy of ≥ 3 months
* Adequate hematologic function
* Parts A and C: Renal function, as follows: serum creatinine ≤ 2.0 mg/dL, or measured 24 hour creatinine clearance of ≥ 45 mL/min
* Part B: Renal function, as follows: creatinine clearance estimate ≥ 15 mL/min and \<60 mL/min by Cockcroft Gault equation adjusted for body weight
* Adequate liver function

Exclusion Criteria:

* Preexisting sensory neuropathy Grade ≥ 2 or motor neuropathy Grade ≥ 2
* Uncontrolled central nervous system metastases
* Use of any investigational drug within 14 days prior to the first dose of study drug
* Any anticancer therapy, including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy or any other agents to treat cancer (anti-hormonal therapy given as adjuvant therapy for early-stage estrogen receptor (ER) positive breast cancer is not considered cancer therapy for the purpose of this protocol)
* Subjects with Immunotherapy related adverse events requiring high doses of steroids (≥ 40 mg/day of prednisone) are not eligible
* Any P-gp inducers/inhibitors or strong CYP3A inhibitors within 14 days prior to the first dose of study drug
* History of thromboembolic events and/or bleeding disorders ≤ 14 days (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) prior to the first dose of study drug
* Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 12 months of study enrollment, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by outpatient medication
* Known HIV or AIDS
* Positive Hepatitis B surface antigen test
* Positive Hepatitis C antibody test
* Decompensated liver disease as evidenced by clinically significant ascites refractory to diuretic therapy, hepatic encephalopathy, or coagulopathy
* Known sensitivity to any of the ingredients of the investigational product AGS15E
* Major surgery within 28 days prior to first dose of study drug
* History of a primary invasive malignancy not listed in the inclusion criteria, which has not been in remission for at least 3 years. The following are exempt from the 3 year limit:

  * Non-melanoma skin cancer;
  * adenocarcinoma of the prostate that has been surgically treated with a post-treatment PSA that is undetectable;
  * cervical carcinoma in situ on biopsy or squamous intraepithelial lesion on Pap smear; and
  * definitively treated, stage I/II ER+ breast cancer
* Active infection requiring treatment ≤ 7 days before first dose of study drug
* History of uncontrolled diabetes mellitus or diabetic neuropathy
* Condition or situation which may put the subject at significant risk, may confound the study results, or may interfere significantly with subject's participation in the study
* Has ocular conditions such as:

  * Active infection or corneal ulcer (e.g., keratitis)
  * Monocularity
  * History of corneal transplantation
  * Contact lens dependent (if using contact lens, must be able to switch to glasses during the entire study duration)
  * Uncontrolled glaucoma (topical medications allowed)
  * Uncontrolled or evolving retinopathy, wet macular degeneration, uveitis, papilledema, or optic disc disorder

Primary outcomes:
measure: Incidence of adverse events
timeFrame: up to 36 months
measure: Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Concentration at the end of infusion (CEOI)
timeFrame: Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months
measure: Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Maximum observed concentration (Cmax)
timeFrame: Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months
measure: Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Trough concentration (Ctrough)
timeFrame: Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months
measure: Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Time to maximum concentration (Tmax)
timeFrame: Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months
measure: Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Partial area under the serum concentration-time curve after first dose and as appropriate (AUC0-7)
timeFrame: Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months
measure: Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Terminal or apparent terminal half-life (t1/2)
timeFrame: Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months
measure: Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Systemic clearance (CL)
timeFrame: Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months
measure: Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Volume of distribution at steady state (Vss)
timeFrame: Days 1-4, 8, 15-18 and 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycles 2 and 3, and Day 1 of subsequent cycles up to an average of 6 months
Secondary outcomes:
measure: Incidence of Anti-Drug Antibody (ADA)
timeFrame: Up to 26 months
measure: Tumor response
timeFrame: Up to 26 months
measure: Objective response rate
timeFrame: Up to 26 months
measure: Disease control rate
timeFrame: Up to 26 months
measure: Progression free survival
timeFrame: Up to 36 months
measure: Duration of response
timeFrame: Up to 36 months
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Site US00006
state: Alabama
city: New Haven
country: United States
facility: Site US00002
state: Connecticut
city: Detroit
country: United States
facility: Site US00001
state: Michigan
city: Saint Louis
country: United States
facility: Site US00003
state: Missouri
city: Buffalo
country: United States
facility: Site US00009
state: New York
city: Pittsburgh
country: United States
facility: Site US00011
state: Pennsylvania
city: Nashville
country: United States
facility: Site US00010
state: Tennessee
city: Seattle
country: United States
facility: Site US00008
state: Washington
city: Vancouver
country: Canada
facility: Site CA00004
state: British Columbia
city: Hamilton
country: Canada
facility: Site CA00007
state: Ontario
city: Toronto
country: Canada
facility: Site CA00005
state: Ontario
Study officials:
affiliation: Astellas Pharma Global Development, Inc.
name: Associate Medical Director
role: STUDY_DIRECTOR
References: